- BMS-813160
-
- $57.00
-
2026-07-27
- CAS:1286279-29-5
- Purity: 99.79%
- Supply Ability: 10g
|
| | BMS813160 Basic information |
| Product Name: | BMS813160 | | Synonyms: | CS-2742;BMS-813160;BMS813160;BMS 813160;N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide;BMS813160;Acetamide, N-[(1R,2S,5R)-5-[(1,1-dimethylethyl)amino]-2-[(3S)-3-[[7-(1,1-dimethylethyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]amino]-2-oxo-1-pyrrolidinyl]cyclohexyl]-;Inhibitor,CC chemokine receptor,CCR,dual antagonist,peritonitis,CD11b,BMS-813160,inflammation,CTX,thioglycollate,BMS813160,inhibit,mouse,oral;BMS-813160, 10 mM in DMSO;BMS-585059 | | CAS: | 1286279-29-5 | | MF: | C25H40N8O2 | | MW: | 484.64 | | EINECS: | | | Product Categories: | | | Mol File: | 1286279-29-5.mol |  |
| | BMS813160 Chemical Properties |
| density | 1.31±0.1 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO:61.0(Max Conc. mg/mL);125.86(Max Conc. mM)
Ethanol:97.0(Max Conc. mg/mL);200.14(Max Conc. mM) | | form | A crystalline solid | | pka | 15.46±0.60(Predicted) | | color | White to off-white | | InChIKey | CMVHFGNTABZQJU-HCXYKTFWSA-N | | SMILES | C(N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](NC2N3N=C(C(C)(C)C)C=C3N=CN=2)C1=O)(=O)C |
| | BMS813160 Usage And Synthesis |
| Description | BMS 813160 is a dual antagonist of chemokine receptor 2 (CCR2) and CCR5 (IC50s = 6.2 and 3.6 nM, respectively, in radioligand binding assays). It inhibits chemotaxis induced by the CCR2 ligand MCP-1 in THP-1 cells the CCR5 ligand MIP-1β in isolated peripheral T cells with IC50 values of 0.8 and 1.1 nM, respectively. BMS 813160 inhibits peritoneal monocyte and macrophage infiltration in an hCCR-2 KI mouse model of thioglycolate-induced peritonitis, with 54% inhibition when administered at a dose of 50 mg/kg twice per day. | | Uses | BMS-813160, a dual CCR2/CCR5 chemokine antagonist. | | in vivo | BMS-813160 (10-160 mg/kg; p.o. twice a day for two days) inhibits the migration of inflammatory monocytes and macrophages in mouse thioglycollate-induced peritonitis model, and shows excellent oral bioavailability[2]. | Animal Model: | Human-CCR2 knock-in C57BL/6 male mice with thioglycollate injection[2] | | Dosage: | 10, 50 and 160 mg/kg | | Administration: | Oral gavage; 10-160 mg/kg twice a day; for two days | | Result: | Dose-dependently reduced inflammatory monocyte and macrophage infiltration in the peritoneum. |
| | IC 50 | CCR5: 3.6 nM (IC50); CCR2: 6.2 nM (IC50) | | References | [1] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.
[2] NORMAN P. A dual CCR2/CCR5 chemokine antagonist, BMS-813160 Evaluation of WO2011046916.[J]. Expert Opinion on Therapeutic Patents, 2011, 21 12: 1919-1924. DOI: 10.1517/13543776.2011.622750 |
| | BMS813160 Preparation Products And Raw materials |
|